Medical Devices APAC

APAC Pharmacogenomic Testing for Psychiatry Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $105.3 Mn Placeholder estimate
Estimate 2025 $117.1 Mn 24.2% of the global market
Projected 2034 $304.4 Mn 160% Adds $187.3 Mn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 60% of 173 Medical Devices markets here
Key players 5
  • APAC is 24.19% of the global market.
  • Among regions, the largest is North America at $233.8 Mn.
  • Fastest growing: APAC (this report) at 11.2% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$187.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing for Psychiatry Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $105.3 Mn — —
2025 (base) $117.1 Mn +$11.8 Mn —
2026 (forecast) $130.2 Mn +$13.1 Mn +11.2%
2027 (forecast) $144.8 Mn +$14.6 Mn +23.7%
2028 (forecast) $161.0 Mn +$16.2 Mn +37.5%
2029 (forecast) $179.1 Mn +$18.0 Mn +52.9%
2030 (forecast) $199.1 Mn +$20.1 Mn +70%
2031 (forecast) $221.4 Mn +$22.3 Mn +89.1%
2032 (forecast) $246.2 Mn +$24.8 Mn +110.2%
2033 (forecast) $273.8 Mn +$27.6 Mn +133.8%
2034 (forecast) $304.4 Mn +$30.7 Mn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Pharmacogenomic Testing for Psychiatry Market Analysis at a glance
Market size, 2025$117.1 Mn placeholder estimate
Forecast, 2034$304.4 Mn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Pharmacogenomic Testing for Psychiatry Market Analysis Executive Summary

Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.

Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).

Bar chart: Asia Pacific Pharmacogenomic Testing for Psychiatry market size, 2024–2034, placeholder estimates. $105.3 Mn in 2024, $117.1 Mn in 2025 and $304.4 Mn in 2034, 11.2% CAGR.
Asia Pacific Pharmacogenomic Testing for Psychiatry market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Pharmacogenomic Testing for Psychiatry Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.

Competitive Landscape for Pharmacogenomic Testing for Psychiatry Market in APAC

The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing for Psychiatry Market in APAC

Pharmacogenomic Testing for Psychiatry in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.

Patients

Suicide rate, per 100,000 people (WHO)
CountryValueYear
Afghanistan3.32023
Australia13.22023
Bangladesh4.32023
China7.92023
India14.02023
Indonesia1.82023
Japan16.52023
Malaysia4.12023
Myanmar3.82023
Nepal14.02023
New Zealand13.42023
Pakistan7.32023
Philippines2.82023
Singapore7.62023
Thailand10.32023
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing for Psychiatry in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing for Psychiatry market in Asia Pacific?
Placeholder estimate: about $117.1 Mn in 2025, rising to about $304.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing for Psychiatry market in Asia Pacific growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing for Psychiatry market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Depression, Anxiety, ADHD, Bipolar Disorder) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing for Psychiatry market?
Key players include Myriad Genetics, Inc., Genomind, OneOme, Tempus and Thermo Fisher Scientific Inc..
What is driving the Pharmacogenomic Testing for Psychiatry market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
How much research is published on Pharmacogenomic Testing for Psychiatry?
PubMed lists 6 papers on Pharmacogenomic Testing for Psychiatry added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on mental health and genomics

See the topic